Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.37 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948300 | 1.00 | CYP17A1 (0.46) | CYP17A1P2RX3AAK1ATRGPR65 | |
| SCHEMBL7855434 | 0.90 | GPR65 (0.40) | CYP17A1P2RX3AAK1GPR65KCNQ3 | |
| SCHEMBL3344049 | 0.88 | AAK1 (0.45) | CYP17A1P2RX3AAK1ATRSYK | |
| SCHEMBL16879643 | 0.85 | ATR (0.44) | P2RX3AAK1ATRMAPKAPK2METAP1 | |
| SCHEMBL29953353 | 0.84 | ATR (0.41) | CYP17A1P2RX3AAK1ATRS1PR3 | |
| SCHEMBL535514 | 0.84 | ATR (0.43) | P2RX3AAK1ATRMAPKAPK2METAP1 | |
| SCHEMBL1581324 | 0.82 | ATR (0.42) | CYP17A1P2RX3AAK1ATRMAPKAPK2 | |
| SCHEMBL29364468 | 0.82 | ATR (0.42) | CYP17A1P2RX3AAK1ATRMAPKAPK2 | |
| SCHEMBL12584018 | 0.82 | MAPKAPK2 (0.43) | P2RX3AAK1ATRMAPKAPK2METAP1 | |
| SCHEMBL18369794 | 0.82 | ATR (0.42) | CYP17A1P2RX3AAK1ATRMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| CN-118591537-A | PARP7 inhibitors | 吉利德科学公司 | 2024-09-03 | — | — | CN | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-7902195-B2 | Pyridine [3,4-b] pyrazinones | PHARMACIA & UPJOHN COMPANY LLC (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2013208-A1 | PYRIDIN[3,4-B]PYRAZINONES | Pfizer Products Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007122466-A1 | PYRIDINE[3,4-B]PYRAZINONES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122466-A1 | PYRIDINE[3,4-B]PYRAZINONES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249615-A1 | Pyridine [3,4-b] Pyrazinones | PFIZER INC | 2007-10-25 | — | — | US | disclosed |
| US-20070249615-A1 | Pyridine [3,4-b] Pyrazinones | PFIZER INC | 2007-10-25 | — | — | US | disclosed |
| US-20070249615-A1 | Pyridine [3,4-b] Pyrazinones | PFIZER INC | 2007-10-25 | — | — | US | disclosed |
| WO-2006126082-A2 | PYRIDINE [3,4-B] PYRAZINONES AS PDE-5 INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006126083-A1 | PYRIDINE [3 , 4-B] PYRAZINONE COMPOUNDS AS PDE-5 INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006126083-A1 | PYRIDINE [3 , 4-B] PYRAZINONE COMPOUNDS AS PDE-5 INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249615-A1 | Pyridine [3,4-b] Pyrazinones | CYP2B6, CYP2D6, CYP4B1 | CYP17A1 3056/4885P2RX3 188/4885AAK1 3712/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | CYP17A1 1011/4885P2RX3 3008/4885AAK1 2312/4885 |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | CYP17A1 3342/4885P2RX3 439/4885AAK1 1366/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | CYP17A1 1011/4885P2RX3 3008/4885AAK1 2312/4885 |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | CYP17A1 3036/4885P2RX3 1388/4885AAK1 721/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | CYP17A1 3036/4885P2RX3 1388/4885AAK1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.